Inzy stock forecast.

Free cash flow. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. 154.20M. -37.63%. Get the latest Incyte Corporation (INCY) real-time ...According to the issued ratings of 19 analysts in the last year, the consensus rating for Incyte stock is Hold based on the current 1 sell rating, 10 hold ratings and 8 buy ratings for INCY. The average twelve-month price prediction for Incyte is $79.94 with a high price target of $100.00 and a low price target of $61.00.Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...Next reporting date. February 23, 2024. EPS forecast (this quarter) -$0.39. Annual revenue (last year) $17.9M. Annual profit (last year) -$229.8M. Net profit margin.Earnings Date. Feb 05, 2024 - Feb 09, 2024. Forward Dividend & Yield. N/A (N/A) Ex-Dividend Date. N/A. 1y Target Est. 74.41. Fair Value is the appropriate price for the shares of a company, based ...

Website. 2015. 56. Doug Treco. https://www.inozyme.com. Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company’s lead product candidate is INZ-701, a soluble, recombinant, genetically ...

Inozyme Pharma (INZY) Stock Forecast and Price Target 2023 S&P 500 4,559.34 DOW 35,390.15 QQQ 389.51 12 crew members are missing, 1 dead after a …View the latest Inozyme Pharma Inc. (INZY) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Symbol Lookup from Yahoo Finance. Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.The stock price for . Inozyme Pharma (NASDAQ: INZY) is $3.205 last updated Today at November 16, 2023 at 6:59 PM UTC. Q Does Inozyme Pharma (INZY) pay a dividend?What this means: Inozyme Pharma Inc (INZY) gets an Overall Rank of 67, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.Incyte is forecast to grow earnings and revenue by 30.9% and 10.8% per annum respectively. EPS is expected to grow by 30.3% per annum. Return on equity is forecast to be 21.9% in 3 years.View the latest Incyte Corp. (INCY) stock price, news, historical charts, analyst ratings and financial information from WSJ.

A high-level overview of Inozyme Pharma, Inc. (INZY) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

16 analysts have issued twelve-month price objectives for Alibaba Group's shares. Their BABA share price targets range from $90.00 to $150.00. On average, they expect the company's share price to reach $129.20 in the next year. This suggests a possible upside of 74.6% from the stock's current price.

4 Wall Street research analysts have issued 12 month price targets for Argo Blockchain's stock. Their ARBK share price targets range from $1.45 to $2.75. On average, they expect the company's stock price to reach $2.23 in the next twelve months. This suggests a possible upside of 90.9% from the stock's current price.Axsome Therapeutics stock price target raised to $76 from $49 at Mizuho. Sep. 7, 2022 at 6:38 a.m. ET by Tomi Kilgore.In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according ...View the latest Inozyme Pharma Inc. (INZY) stock price, news, historical charts, analyst ratings and financial information from WSJ. The core CPI, excluding food and energy, rose 4.8% from the prior year, also slowing from 5.3% in May and below the consensus forecast. The Dow rose 0.8%, the S&P 1.0%, and the Nasdaq 1.4%. Crude ...

Based on 12 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $82.64 with a high forecast of $93.00 and a low forecast of $63.00. The average price target represents a 53.24% change from the last price of $53.93. Highest Price Target $93.00. Average Price Target $82.64.Next reporting date. February 23, 2024. EPS forecast (this quarter) -$0.39. Annual revenue (last year) $17.9M. Annual profit (last year) -$229.8M. Net profit margin.These Healthcare stocks are trading lower: -NanoViricides Inc ( NNVC) stock is trading at $1.35, a loss of $0.28, or 17.18%, on high volume. Nanoviricides Inc gets a Sentiment Score of Very Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $5.25. -180 Life Sciences Corp ( …We've seen plenty of personal finance tools designed to help you track what you're spending, but web site PocketSmith is an impressive new web-based personal finance tool with an emphasis on forecasting your financial future. We've seen ple...Nov 14, 2023 · Inozyme Pharma Stock Forecast and Price Target. The average price target for Inozyme Pharma's stock set by recognized analysts recently is $23.00, which would result in a potential upside of approximately 701.39% if it reached this mark. The estimation is based on a high estimate of $40.00 and a low estimate of $5.00. According to our current INZY stock forecast, the value of Inozyme Pharma shares will rise by 7.27% and reach $ 3.50 per share by November 24, 2023. According to our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).Based on short-term price targets offered by 15 analysts, the average price target for Incyte comes to $78.00. The forecasts range from a low of $59.00 to a high of $93.00. The average price ...

Discover historical prices for INZY stock on Yahoo Finance. View daily, weekly or monthly format back to when Inozyme Pharma, Inc. stock was issued.Incyte Corp. Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib).

Find the latest Avenue Therapeutics, Inc. (ATXI) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest VYNE Therapeutics Inc. (VYNE) stock quote, history, news and other vital information to help you with your stock trading and investing.Inozyme Pharma stock forecast report. View INZY price target, analyst ratings, upgrades & downgrades predictions, and buy or a sell data.Find the latest Cano Health, Inc. (CANO) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest Alzamend Neuro, Inc. (ALZN) stock quote, history, news and other vital information to help you with your stock trading and investing.The stock price for . Inozyme Pharma (NASDAQ: INZY) is $3.205 last updated Today at November 16, 2023 at 6:59 PM UTC. Q Does Inozyme Pharma (INZY) pay a dividend?Feb-04-23 07:04AM. Institutions profited after Inozyme Pharma, Inc.'s (NASDAQ:INZY) market cap rose US$19m last week butprivate equity firms profited the most. (Simply Wall St.) Jan-09-23 08:30AM. Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress. (GlobeNewswire) -9.68%.Dec 2, 2023 · The consensus price target of analysts on Wall Street is $21.00, which implies an increase of 81.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $15.00 and $40.00 respectively. As a result, INZY is trading at a discount of -938.96% off the target high and -289.61% off the low.

The high estimate for the stock price was $93.00, while the low estimate was $58.00. This indicates a potential increase of 32.98% from the last recorded price of $53.39. The consensus among 23 polled investment analysts is to hold the stock in Incyte Corp. This rating has remained steady since November, when it was downgraded from a buy rating.

Inozyme Pharma Inc (INZY) stock has fallen -6.11% while the S&P 500 is higher by 0.28% as of 3:14 PM on Monday, Apr 3. INZY is down -$0.35 from the previous closing price of $5.73 on volume of 1,192,651 shares. Over the past year the S&P 500 is down -10.08% while INZY is higher by 25.12%. INZY lost -$1.78 per share in the over the …

What this means: Inozyme Pharma Inc (INZY) gets an Overall Rank of 67, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. Delayed Data. As of Nov 16. +0.03 / +0.94%. Today’s Change. 0.99. Today ||| 52-Week Range. 7.33. +207.62%. Year-to-Date.Find the latest Incyte Corporation (INCY) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo FinanceForecast . Price target. 21.00 0.00 0.00%. The 6 analysts offering 1 year price forecasts for INZY have a max estimate of — and a min estimate of —. Analyst rating. Based on 7 analysts giving stock ratings to INZY in the past 3 months. EPS. Annual Annual Quarterly Quarterly More MoreNovember 29, 2023 at 2:12 PM PST. Listen. 1:37. Victoria’s Secret & Co. reported a larger-than-expected quarterly loss amid a rise in investment in marketing and technology, …According to 42 stock analysts, the average 12-month stock price forecast for Amazon stock is $170.76, which predicts an increase of 16.14%. The lowest target is $116 and the highest is $230. On average, analysts rate Amazon stock as a strong buy. Analyst Consensus: Strong Buy. Target Low Average Median High; Price: $116: $170.76: …Find the latest Cabaletta Bio, Inc. (CABA) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest Moleculin Biotech, Inc. (MBRX) stock quote, history, news and other vital information to help you with your stock trading and investing.Earnings Date. Feb 05, 2024 - Feb 09, 2024. Forward Dividend & Yield. N/A (N/A) Ex-Dividend Date. N/A. 1y Target Est. 74.41. Fair Value is the appropriate price for the shares of a company, based ... Find the latest VYNE Therapeutics Inc. (VYNE) stock quote, history, news and other vital information to help you with your stock trading and investing.Deutsche Bank has become the latest big name on Wall Street to issue a bullish stock-market forecast for 2024, with analysts predicting the S&P 500 will soar to …Overview Inozyme Pharma Inc. U.S.: Nasdaq Add to Watchlist

Click here to know why INCY stock is a buy. Incyte's core business looks solid. Opzelura's sales start is impressive, but revenue is low due to high discounts. ... 2022 forecast. According to ...Inozyme Pharma, Inc. (INZY) stock forecast and price target. Find the latest Inozyme Pharma, Inc. INZY analyst stock forecast, price target, and recommendation trends with in-depth analysis from ... Find the latest Phathom Pharmaceuticals, Inc. (PHAT) stock quote, history, news and other vital information to help you with your stock trading and investing.Instagram:https://instagram. learn trade optionssmall cap shares to buyvalueable quartershow much is 1 gold brick worth Find the latest Cano Health, Inc. (CANO) stock quote, history, news and other vital information to help you with your stock trading and investing. a g gfinancial advisor knoxville tn Incyte Corp. Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). how much is 1 gold coin worth SEMR | Complete SEMrush Holdings Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Inozyme Pharma Inc (INZY) stock has fallen -6.11% while the S&P 500 is higher by 0.28% as of 3:14 PM on Monday, Apr 3. INZY is down -$0.35 from the previous closing price of $5.73 on volume of 1,192,651 shares. Over the past year the S&P 500 is down -10.08% while INZY is higher by 25.12%. INZY lost -$1.78 per share in the over the …